PepGen Inc (PEPG) Stock Analysis
Verdict: AVOID
Binary clinical risk meets imminent dilution—PEPG’s valuation floor depends on IDMC-15 data vs. the looming $400M shelf overhang.
Investment score: 38/100
Analysis as of
Is PepGen Inc stock worth reviewing? AI model thesis
PEPG is a pre-revenue biotech facing a liquidity crunch, evidenced by a $400M shelf filing that effectively caps upside despite promising EDO technology.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
PepGen Inc opportunities and risks
What speaks for PEPG
- Positive IDMC-15 Data Catalyst
What speaks against PEPG
- Massive Shareholder Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PEPG | n/a | 0.0x | n/a | 0.0% | 0.0% | -74.0% |
| INO | n/a | 0.0x | n/a | 0.0% | 0.0% | -115.5% |
| CADL | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.2% |
| KLRS | n/a | 0.0x | n/a | 0.0% | 0.0% | -53.3% |
| CBUS | n/a | 14.6x | n/a | 72.1% | -2366.3% | -80.7% |
| BMEA | n/a | 0.0x | n/a | 0.0% | 0.0% | -66.6% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -66.6% |
Frequently asked questions about PepGen Inc (PEPG)
Is PEPG stock a good investment?
The cached TradeMates AI model rates PepGen Inc as AVOID with an investment score of 38/100. PEPG is a pre-revenue biotech facing a liquidity crunch, evidenced by a $400M shelf filing that effectively caps upside despite promising EDO technology. This is algorithmic model output, not personal investment advice.
Is PEPG stock a buy?
The TradeMates model verdict for PEPG is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.